logo-loader
viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals granted TGA approval for short-term insomnia treatment ZolpiMist™

The TGA approval, which has been achieved ahead of the projected Q4 2020 schedule, enables ZolpiMist™ to be sold in Australia.

SUDA Pharmaceuticals Ltd - SUDA Pharmaceuticals receives TGA approval for the registration of ZolipMist™
The approval also allows for a competitive supply price

SUDA Pharmaceuticals Ltd (ASX:SUD) has received Therapeutics Goods Administration (TGA) approval for registration of its lead product ZolpiMist™ for the treatment of short-term insomnia in adults.

TGA approval enables ZolpiMistTM to be sold in Australia, enables a more competitive supply price and supports corresponding submissions in additional territories.

Following a Marketing Authorisation Application (MAA) submission to the TGA for ZolpiMist™ in April 2019, the company made a strategic decision to register a supplemental active pharmaceutical ingredient supplier and final product manufacturer.

This required an amendment to the TGA submission.

TGA approval includes the supplemental API supplier and final product manufacturer, which allows SUDA to supply the product at a more competitive supply price and potentially allows the company to target additional territories.

“Looking forward” to commercial sales

Chief executive officer and managing director Dr Michael Baker said: “The TGA submission was a combined effort by SUDA’s technical team as well as our regulatory consultant, Pharma To Market.

“Obtaining the approval indicates the calibre of our staff and is also a key benefit to our partners for ZolpiMist™.

“We are delighted by the outcome and look forward to seeing the commencement of commercial sales in the foreseeable future.”

Benefits of TGA approval

The benefits of TGA approval are:

  • ZolpiMist™ will be included on the Australian Register of Therapeutic Goods and can be commercialised and supplied within Australia;
  • Demonstrates SUDA’s compliance with Good Manufacturing Practice and an ability to obtain regulatory approvals for its products; and
  • It will assist current partners, TEVA, Mitsubishi Tanabe Pharma Singapore and MTP Korea, in submissions in their respective territories with the amended API supplier and manufacturer.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.039 AUD

ASX:SUD
Market: ASX
Market Cap: $11.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

1 week, 5 days ago

2 min read